Leukemia, Lymphocytic, Chronic, B-Cell
Showing NaN - NaN of 6
Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Leukemia Trial in Worldwide (MT-3724
Terminated
- Non-Hodgkin's B-cell Lymphoma
- +5 more
- MT-3724 Phase 1
- MT-3724 Phase 2
-
Tucson, Arizona
- +40 more
Jul 18, 2022
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma Trial in Worldwide (BMS-986403, Fludarabine, Cyclophosphamide)
Recruiting
- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma
- BMS-986403
- +2 more
-
Birmingham, Alabama
- +24 more
Jul 6, 2022
Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell Trial in Worldwide (Durvalumab, Lenalidomide, Rituximab)
Active, not recruiting
- Lymphoma
- Leukemia, Lymphocytic, Chronic, B-Cell
- Durvalumab
- +4 more
-
Gilbert, Arizona
- +53 more
Jan 25, 2022
Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Worldwide
Completed
- Leukemia, Lymphocytic, Chronic, B-Cell
- +2 more
- Tafasitamab
- +2 more
-
Jacksonville, Florida
- +16 more
Dec 10, 2021
Leukemia, Lymphocytic, Chronic, B-Cell Trial in Worldwide (CC-122, Ibrutinib, Obinutuzumab)
Completed
- Leukemia, Lymphocytic, Chronic, B-Cell
- CC-122
- +2 more
-
La Jolla, California
- +23 more
Aug 20, 2021
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular Trial in Worldwide (Part 1 (Dose
Terminated
- Leukemia, Lymphocytic, Chronic, B-Cell
- +4 more
- Part 1 (Dose Escalation): Duvortuxizumab
- Part 2 (Dose Expansion): Duvortuxizumab
-
Detroit, Michigan
- +19 more
Dec 19, 2018